AstraZeneca is shelling out up to $1.5 billion to lock down global rights to an EGFR lung cancer drug from Dizal Pharmaceutical, deepening its ties with a Chinese biotech it spun out nearly a decade ago.
Source: FiercePharma
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.